Preclinical studies demonstrated that JAK kinase inhibitors can be used in B-ALL with activated JAK-STAT signaling such as in B-ALL with CRLF2 rearrangements and JAK gene mutations [87]. Here, CRLF2 is linked to acute lymphoblastic leukemia.